EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome

Kristen S Fisher, Alexander Ankar, Jon Cokley, Eyal Muscal iD, James J Riviello, Yi-Chen Lai iD

Annals of Clinical and Translational Neurology · 2025-04 · 12 (4) · 871-875

DOI: 10.1002/acn3.70011 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 11.02.2025. Verfasst von Kristen S Fisher und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Te…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dexamethasone, Immunotherapy, Interleukin 1 Receptor Antagonist Protein. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Febrile infection related epilepsy syndrome (FIRES) is a rare presentation of refractory status epilepticus with immune dysregulation as a potential pathologic mechanism. Despite promising results from second‐line immunomodulators, approximately 30% remain refractory to treatment. We describe two children with FIRES who were unable to wean from anesthetic infusions with immunomodulatory treatment and subsequently received concurrent intrathecal dexamethasone and anakinra/tocilizumab as escalation of therapy. Following the initiation of this combined regimen, anesthetic infusions were decreased while maintaining seizure freedom. These cases demonstrate proof of principle that a multi‐modal approach may be beneficial and should be considered in the treatment of FIRES.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDexamethasoneImmunotherapyInterleukin 1 Receptor Antagonist ProteinSeizures, FebrileStatus EpilepticusChild, PreschoolHumansMaleDrug Resistant EpilepsyDrug Therapy, CombinationInjections, SpinalChild

Stichwörter der Autor:innen

CNS immune modulationanakinrafebrile infection related epilepsy syndrome (FIRES)intrathecal dexamethasonenew onset refractory status epilepticus (NORSE)systemic immune modulationtocilizumab

Substanzen

Antibodies, Monoclonal, HumanizedDexamethasoneInterleukin 1 Receptor Antagonist Proteintocilizumab

Autor:innen und Institutionen

  • Division of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA.
  • Department of Pharmacy, Texas Children's Hospital, Houston, Texas, USA.
  • Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA.
  • Division of Pediatric Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine at Texas Children's Hospital, Houston, Texas, USA.

ORCID-Profile: Eyal Muscal, Yi-Chen Lai

Zitieren

APA

Fisher, K. S., Ankar, A., Cokley, J., Muscal, E., Riviello, J. J., & Lai, Y. C. (2025). Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome. Annals of Clinical and Translational Neurology, 12(4), 871-875. https://doi.org/10.1002/acn3.70011

Vancouver

Fisher KS, Ankar A, Cokley J, Muscal E, Riviello JJ, Lai YC. Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome. Annals of Clinical and Translational Neurology. 2025;12(4):871-875. doi:10.1002/acn3.70011

BibTeX
@article{Fisher2025,
  author = {Fisher, Kristen S and Ankar, Alexander and Cokley, Jon and Muscal, Eyal and Riviello, James J and Lai, Yi-Chen},
  title = {Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {4},
  pages = {871--875},
  doi = {10.1002/acn3.70011}
}
Kostenlos starten →